|
(PQA1) Molecular Mechanism of Metformin in Cancer
|
5R21CA184704-02
|
$228,375
|
$228,375
|
DAI, CHENGKAI
|
JACKSON LABORATORY
|
|
(PQB-4) Opposing Effects of the SASP in Cancer Progression
|
5R01CA184572-02
|
$329,925
|
$112,175
|
HERBIG, UTZ
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
(PQB2) Identification of Tumor-Derived Activators of Anti-Cancer Immune Responses
|
5R21CA190072-02
|
$180,843
|
$180,843
|
SUNWOO, JOHN
|
STANFORD UNIVERSITY
|
|
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma
|
5R01CA185072-02
|
$366,691
|
$366,691
|
SEKULIC, ALEKSANDAR
|
MAYO CLINIC ARIZONA
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-02
|
$692,567
|
$692,567
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis
|
5R01CA185189-02
|
$483,693
|
$483,693
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-02
|
$405,890
|
$405,890
|
SHARPLESS, NORMAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
2U54CA132379-06A1
|
$1,379,196
|
$206,879
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
A comparison of interventions to teach melanoma patients' skin self-examination
|
5R01CA154908-05
|
$515,336
|
$515,336
|
ROBINSON, JUNE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-07
|
$250,535
|
$250,535
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A novel in vivo model system of melanoma using a human-mouse neural crest cell ch
|
1F32CA196065-01
|
$52,406
|
$52,406
|
WERT, KATHERINE
|
WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
|
|
A novel NKG2D-specific BiTE cancer immunotherapy
|
5R01CA164178-03
|
$336,150
|
$168,075
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
|
A novel preclinical model of spontaneous metastasis
|
ZIA BC 011167
|
$458,649
|
$435,717
|
Merlino, Glenn
|
CCR (NCI)
|
|
A Platform for Real-time Drug Profiling of Patient-Derived Melanomas
|
5F32CA180569-02
|
$57,962
|
$57,962
|
NUSSBAUM, DANIEL
|
DUKE UNIVERSITY
|
|
A research and training program for junior clinicians in treating metastatic mela
|
5K24CA172123-03
|
$156,084
|
$156,084
|
KLUGER, HARRIET
|
YALE UNIVERSITY
|
|
A role for c-Abl/Arg in melanoma progression
|
5R01CA166499-04
|
$308,604
|
$308,604
|
PLATTNER, RINA
|
UNIVERSITY OF KENTUCKY
|
|
A Self-Regulation Approach to an Indoor Tanning Intervention for Frequent Users
|
5K07CA175115-02
|
$137,183
|
$137,183
|
STAPLETON, JEROD
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-39S1
|
$62,498
|
$3,125
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-39S2
|
$125,000
|
$6,250
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-39
|
$7,704,373
|
$385,219
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Accuracy in the Diagnosis of Melanoma & the Impact of Double Reading
|
5R01CA151306-05
|
$767,869
|
$767,869
|
ELMORE, JOANN
|
UNIVERSITY OF WASHINGTON
|
|
Adaptive regulation of cancer cell fate following oncogene inhibition
|
1K99CA194163-01
|
$120,183
|
$120,183
|
FALLAHI-SICHANI, MOHAMMAD
|
HARVARD MEDICAL SCHOOL
|
|
Adaptive signaling exposes a therapeutic vulnerability in NRAS melanomas
|
5R21CA182020-02
|
$171,825
|
$171,825
|
WEBER, MICHAEL
|
UNIVERSITY OF VIRGINIA
|
|
Adoptive Cell Therapy with Rejuvenated Antigen-specific T Cells
|
1K08CA197966-01
|
$174,960
|
$174,960
|
ITO, FUMITO
|
UNIVERSITY OF MICHIGAN
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,731,003
|
$1,557,902
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research
|
5U24CA180921-03
|
$638,721
|
$127,744
|
CROWLEY, REBECCA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
An innovative, curriculum-based integrated sun exposure behavior intervention fo
|
5R01CA158407-04
|
$608,162
|
$608,162
|
COCKBURN, MYLES
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
An Internet-Based Behavioral Intervention for Individuals Diagnosed with Melanoma
|
5R01CA171666-02
|
$525,739
|
$525,739
|
COUPS, ELLIOT
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Analysis of cap-dependent translational repression by microRNAs in oncogensis
|
5R01CA140986-05
|
$326,813
|
$326,813
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
Analysis of the Signaling and Mechanical Cues Promoting Invasion in Melanoma
|
5U01CA155758-06
|
$330,540
|
$330,540
|
LEVCHENKO, ANDRE
|
YALE UNIVERSITY
|
|
Analyzing the Efficacy of Galectin-1 Ligand Inhibition in Adoptive T cell Therapy
|
5F31CA171520-03
|
$35,046
|
$35,046
|
SWEENEY, JENNA
|
HARVARD MEDICAL SCHOOL
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$1,054,639
|
$316,392
|
DuBois, Wendy
|
CCR (NCI)
|
|
Animal Model Development-CAPR infrastructure
|
ZIC BC 011137
|
$1,002,841
|
$100,284
|
Van Dyke, Terry
|
CCR (NCI)
|
|
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis
|
5R01CA092160-14
|
$297,491
|
$148,746
|
TIGYI, GABOR
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AID
|
ZIA SC 004020
|
$2,372,042
|
$450,688
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Arf6 inhibitors for the treatment of uveal melanoma
|
1R43CA192545-01A1
|
$298,731
|
$298,731
|
MUELLER, ALAN
|
NAVIGEN, INC.
|
|
Arginase Production in Cancer: Evading Immune Response
|
5R01CA107974-10
|
$294,654
|
$73,664
|
OCHOA, AUGUSTO
|
LSU HEALTH SCIENCES CENTER
|
|
ATF2 Oncogenic Addiction in Melanoma
|
5R01CA172017-03
|
$404,625
|
$404,625
|
RONAI, ZE'EV
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
Automated Image Guidance for Diagnosing Skin Cancer With Confocal Microscopy
|
1R01CA199673-01
|
$658,985
|
$658,985
|
RAJADHYAKSHA, MILIND
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
b-catenin in vaccine-induced anti-tumor CD8 T cell immunity
|
1R01CA198105-01
|
$401,456
|
$200,728
|
JIANG, AIMIN
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
B7-H1 Signaling in Ovarian Cancer
|
5R01CA164122-04
|
$310,213
|
$124,085
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
Bacterial Minicells for Cancer Therapeutics
|
5F32CA165657-02
|
$27,930
|
$9,217
|
DANINO, TAL
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Basic and Preclinical Animal Models in support of Cancer and HIV/AIDS Research
|
ZIG BC 010856
|
$14,530,484
|
$726,524
|
Custer, Mary
|
CCR (NCI)
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-09
|
$3,155,163
|
$94,655
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S2
|
$112,151
|
$3,365
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S3
|
$183,048
|
$5,491
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Bifunctional Antibodies for Melanoma Therapy
|
5R01CA177719-02
|
$442,736
|
$442,736
|
GLAZER, PETER
|
YALE UNIVERSITY
|
|
Biology of Melanoma Metastasis
|
5R01CA047159-24
|
$329,003
|
$329,003
|
HERLYN, MEENHARD
|
WISTAR INSTITUTE
|
|
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy
|
5R01CA184845-02
|
$340,821
|
$340,821
|
HWU, PATRICK
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
BLIMP-1 mediated regulation of CD8+ TIL
|
3R01CA166458-03S2
|
$72,734
|
$36,367
|
BULLOCK, TIMOTHY
|
UNIVERSITY OF VIRGINIA
|
Total relevant funding to Melanoma for this search: $132,793,176
|